ASCO Review: A Closer Look At Value By Tumor Type
ASCO's big push on providing value came through loud and clear in annual meeting sessions on multiple myeloma, breast cancer, colon cancer and renal cell carcinoma.
You may also be interested in...
Tools that provide transparent, comparative information about the efficacy, drawbacks and costs of a range of treatment options are helping patients, clinicians and payers choose drugs wisely. They're also forcing pharma to link price more explicitly to value.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.